Search Results

There are 10853 results for: content related to: Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy

  1. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: A double-blind, randomized, placebo-controlled trial

    Head & Neck

    Dominik Riss, Martin Burian, Axel Wolf, Veronika Kranebitter, Alexandra Kaider and Christoph Arnoldner

    Article first published online : 30 APR 2014, DOI: 10.1002/hed.23655

  2. Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis

    The Laryngoscope

    Volume 121, Issue 3, March 2011, Pages: 644–646, Sonia Chen IV, Tom Karnezis and Terence M. Davidson

    Article first published online : 11 NOV 2010, DOI: 10.1002/lary.21345

  3. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: Effectiveness of an injection protocol based on the vascular anatomy of the nose

    The Laryngoscope

    Volume 122, Issue 6, June 2012, Pages: 1210–1214, Sinan Dheyauldeen, Amy Østertun Geirdal, Terje Osnes, Liv Sofie Vartdal and Ralph Dollner

    Article first published online : 7 MAY 2012, DOI: 10.1002/lary.23303

  4. You have free access to this content
    Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas

    Cancer

    Volume 116, Issue 17, 1 September 2010, Pages: 3988–3999, Marc C. Chamberlain

    Article first published online : 19 AUG 2010, DOI: 10.1002/cncr.25256

  5. Successful management of chronic gastrointestinal hemorrhage using bevacizumab in the setting of hereditary hemorrhagic telangiectasia

    American Journal of Hematology

    Volume 90, Issue 6, June 2015, Pages: 561–563, Mary E. Sehl, Theresa M. Gruber, Justin P. McWilliams and Victor J. Marder

    Article first published online : 10 MAY 2015, DOI: 10.1002/ajh.23969

  6. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases

    British Journal of Surgery

    Volume 98, Issue 3, March 2011, Pages: 399–407, D. A. Wicherts, R. J. de Haas, M. Sebagh, E. Saenz Corrales, D. L. Gorden, F. Lévi, B. Paule, D. Azoulay, D. Castaing and R. Adam

    Article first published online : 15 DEC 2010, DOI: 10.1002/bjs.7368

  7. Retina, Vitreous

    Clinical & Experimental Ophthalmology

    Volume 36, Issue s1, June 2008, Pages: A459–A584,

    Article first published online : 18 JUL 2008, DOI: 10.1111/j.1442-9071.2008.01760.x

  8. Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis

    The Laryngoscope

    Volume 121, Issue 3, March 2011, Pages: 636–638, Tom T. Karnezis and Terence M. Davidson

    Article first published online : 16 DEC 2010, DOI: 10.1002/lary.21415

  9. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration

    Intervention Review

    The Cochrane Library

    Sharon D Solomon, Kristina Lindsley, Satyanarayana S Vedula, Magdalena G Krzystolik and Barbara S Hawkins

    Published Online : 29 AUG 2014, DOI: 10.1002/14651858.CD005139.pub3

  10. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia

    The Laryngoscope

    Volume 119, Issue 5, May 2009, Pages: 988–992, Jana Simonds, Frank Miller, Jess Mandel and Terence M. Davidson

    Article first published online : 4 FEB 2009, DOI: 10.1002/lary.20159

  11. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

    Intervention Review

    The Cochrane Library

    Lorenzo Moja, Ersilia Lucenteforte, Koren H Kwag, Vittorio Bertele, Annalisa Campomori, Usha Chakravarthy, Roberto D'Amico, Kay Dickersin, Laurent Kodjikian, Kristina Lindsley, Yoon Loke, Maureen Maguire, Daniel F Martin, Alessandro Mugelli, Bernd Mühlbauer, Isabel Püntmann, Barnaby Reeves, Chris Rogers, Christine Schmucker, Manju L Subramanian and Gianni Virgili

    Published Online : 15 SEP 2014, DOI: 10.1002/14651858.CD011230.pub2

  12. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer

    Intervention Review

    The Cochrane Library

    Anna Dorothea Wagner, Christoph Thomssen, Johannes Haerting and Susanne Unverzagt

    Published Online : 11 JUL 2012, DOI: 10.1002/14651858.CD008941.pub2

  13. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model

    Journal of Evaluation in Clinical Practice

    Volume 18, Issue 2, April 2012, Pages: 247–255, Jignesh J. Patel, Margaret A.S. Mendes, Mark Bounthavong, Melissa L.D. Christopher, Daniel Boggie and Anthony P. Morreale

    Article first published online : 16 SEP 2010, DOI: 10.1111/j.1365-2753.2010.01546.x

  14. You have free access to this content
    Bevacizumab: Finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia

    Hepatology

    Volume 58, Issue 1, July 2013, Pages: 442–445, Lawrence H. Young, Katharine J. Henderson, Robert I. White and Guadalupe Garcia-Tsao

    Article first published online : 31 MAY 2013, DOI: 10.1002/hep.26472

  15. You have free access to this content
    Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection

    Acta Ophthalmologica

    Volume 91, Issue 4, June 2013, Pages: e304–e310, Yu Xu, Qi Zhang, Xiaoli Kang, Ying Zhu, Jiakai Li, Yiye Chen and Peiquan Zhao

    Article first published online : 7 MAY 2013, DOI: 10.1111/aos.12055

  16. Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery

    Acta Ophthalmologica

    Tine Van Bergen, Evelien Vandewalle, Lieve Moons and Ingeborg Stalmans

    Article first published online : 18 MAY 2015, DOI: 10.1111/aos.12766

  17. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab

    Cancer

    Volume 121, Issue 9, May 1, 2015, Pages: 1456–1462, Jim Zhong, Arif N. Ali, Alfredo D. Voloschin, Yuan Liu, Walter J. Curran Jr, Ian R. Crocker and Hui-Kuo G. Shu

    Article first published online : 29 DEC 2014, DOI: 10.1002/cncr.29234

  18. Anti-angiogenic therapies for metastatic colorectal cancer

    Intervention Review

    The Cochrane Library

    Anna Dorothea ADW Wagner, Dirk Arnold, Axel AG Grothey, Johannes Haerting and Susanne Unverzagt

    Published Online : 8 JUL 2009, DOI: 10.1002/14651858.CD005392.pub3

  19. Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

    Cancer

    Volume 121, Issue 7, April 1, 2015, Pages: 997–1007, Kathryn M. Field, Justin T. Jordan, Patrick Y. Wen, Mark A. Rosenthal and David A. Reardon

    Article first published online : 26 SEP 2014, DOI: 10.1002/cncr.28935

  20. Antiangiogenic therapy for high-grade glioma

    Intervention Review

    The Cochrane Library

    Mustafa Khasraw, Malaka S Ameratunga, Robin Grant, Helen Wheeler and Nick Pavlakis

    Published Online : 22 SEP 2014, DOI: 10.1002/14651858.CD008218.pub3